ESR1
    ESR2
    ESR3
    ESR4
    ESR5
    ESR6
    ESR7
    ESR8
    ESR9
    ESR10
    ESR11
    ER1
    ER2
    ER3


Project Co-ordinator:

Prof. Leszek Kaczmarek
http://neurogene.nencki.gov.pl
l.kaczmarek@nencki.gov.pl
Nencki Institute
Warsaw, POLAND

 

Project Manager:

Ms. Marta Rucinska
m.rucinska@nencki.gov.pl
Nencki Institute
Warsaw, POLAND

 

Recruitment Co-ordinator

Prof. Alexander Dityatev
alexander.dityatev@dzne.de
Deutsches Zentrum fur
Neurodegenerative Erkrankungen
Magdeburg, GERMANY

 

Training Co-ordinator

Prof. Robert Pawlak
R.Pawlak@exeter.ac.uk
University of Exeter Medical School
Exeter, UK

ESR11: New immunotherapy tools against AD (lead: SVIDA, partners: DZNE-2b, DZNE-2a)

Adrian Posado Fernandez

adrian.posado@icloud.com

adrian.jpg

 

 

 

 

 

Nowadays, Alzheimer disease (AD) is the fourth-leading cause of death in adults after heart disease, cancer and stroke in the world. It is estimated that there were 24.3 million people with dementia in the world in 2001, with majority suffering from AD and vascular dementia, and predicted that this would rise to 42 million in 2020 and 81 million by 2040. AD is a disorder characterized by the accumulation of amyloid plaques and neuro fibrillary tangles in specific regions of the brain. Current therapeutic options for AD, however, are limited and to date none have provided a cure. Among the most promising approaches to date are active and passive immunotherapeutic interventions that limits cerebral amyloid beta deposition and/or accelerate its clearance, but their safety profile is still discussed.The design, production (laboratory scale) and characterization of several murine monoclonal antibodies against amyloid beta and tau protein will be carried on our laboratories. Moreover, preclinical tests of different approaches for immunotherapy applying nanotechnology in AD will be performed in collaboration with several international partners.

 STAB VIDA information

1)Profile

STAB VIDA is a portuguese biotech company(www.stabvida.commainly focused on DNA and RNA-seq analysis and antibodies production. Our main applications are the diagnostic and personalized medicine for Alzheimer disease and Lung cancer.

 2Main publications:

Markoutsa E, Papadia K, Clemente CFlores O, Antimisiaris SG, 2012: Anti-Aβ-MAb and dually decorated nanoliposomes: effect of Aβ1-42 peptides on interaction with hCMEC/D3 cells, Eur J Pharm Biopharm, May;81(1):49-56. doi: 10.1016/j.ejpb.2012.02.006. Epub 2012 Feb 22

 

Canovi M, Markoutsa E, Lazar AN, Pampalakis G,Clemente C, Re F, Sesana S,  Masserini M, Salmona M, Duyckaerts C, Flores O, Gobbi M, Antimisiaris SG,  2011: The binding affinity of anti-A_1-42 MAb-decorated nanoliposomes to A_1-42 peptides in vitro and to amyloid deposits in post-mortem tissue, Biomaterials, Aug;32(23):5489-97. Epub 2011 May 6

 

Le Droumaguet B, Nicolas J, Brambilla D, Mura S, Maksimenko A, De Kimpe L, Salvati E, Zona C, Airoldi C, Canovi M, Gobbi M, Magali N, La Ferla B, Nicotra F,Scheper W, Flores O, Masserini M, Andrieux K, Couvreur P, 2012Versatile and efficient targeting using a single nanoparticulate platform: application to cancer and Alzheimer's diseaseACS Nano.Jul 24;6(7):5866-79. Epub 2012 Jul 2